EP0000100B1 - Acides 7-acylamino-3-(1-(2-sulfamylaminoéthyl)-tétrazole-5-ylthiométhyl)-3-céphem-4-carboxyliques, un procédé pour leur préparation et leurs compositions pharmaceutiques - Google Patents
Acides 7-acylamino-3-(1-(2-sulfamylaminoéthyl)-tétrazole-5-ylthiométhyl)-3-céphem-4-carboxyliques, un procédé pour leur préparation et leurs compositions pharmaceutiques Download PDFInfo
- Publication number
- EP0000100B1 EP0000100B1 EP78300031A EP78300031A EP0000100B1 EP 0000100 B1 EP0000100 B1 EP 0000100B1 EP 78300031 A EP78300031 A EP 78300031A EP 78300031 A EP78300031 A EP 78300031A EP 0000100 B1 EP0000100 B1 EP 0000100B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- sulfamoylaminoethyl
- cephem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 0 *[n]1nnnc1S Chemical compound *[n]1nnnc1S 0.000 description 2
- NNOJMKHGNISXLA-ALCCZGGFSA-N CC(C)=N/N=N\C Chemical compound CC(C)=N/N=N\C NNOJMKHGNISXLA-ALCCZGGFSA-N 0.000 description 1
- OSMHBAWJLFLLRZ-UHFFFAOYSA-N CNCC[NH+](C)[O-] Chemical compound CNCC[NH+](C)[O-] OSMHBAWJLFLLRZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/36—Methylene radicals, substituted by sulfur atoms
Definitions
- This invention relates to cephalosporin compounds having antibacterial activity, processes for their preparation, pharmaceutical compositions containing them for use as antibacterial agents.
- Cephalosporin derivatives having specific tetrazolylthiomethyl substituents at position 3 of the cephem nucleus are known.
- West German Offenlegungsschrift No. 2649545 discloses cephalosporin derivatives of general formula: where W is hydrogen or a methoxy group and R 1 is where X is thienyl, dihydrophenyl, phenyl or phenyl monosubstituted with hydroxy, hydroxymethyl, formamido or ureido; A is NH 2 , OH, COOH, S0 3 H or when X is a phenyl group a formyloxy group; Y is thienyl, tetrazolyl, sydnonyl, cyano or o-aminomethylphenyl; Z is a methyl, trifluoromethyl, trifluoroethyl, cyanomethyl or pyridyl group; M is 0, 1 or 2 and N is 2, 3, 4
- the compounds of this invention differ from previously known cephalosporins in general and those of the above Offenlegungsschrift in particular principally because they have a 1-(2-sulfamoylaminoethyl)tetrazolyl-5-thiomethyl substituent at position 3 of the cephem nucleus.
- esters of the carboxylic acid group include simple alkyl and aryl esters as well as esters which are cleaved within the body to the parent acid such as indanyl, pivaloyloxymethyl, acetoxymethyl, propionyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl and thienylglycyloxymethyl esters and others. Accordingly, by an ester of a compound of formula (I) we mean esters of one or more of these groups. All such ester derivatives are included within the scope of this invention.
- amide derivatives of the compounds of formula (I) are also covered in this invention.
- a pharmaceutically acceptable amide derivative we mean an amide derivative at an amino group contained in a 7-phenylglycylamino group, for example the furyl-, pyranyl-, oxolanyl- or oxiranyl- carbonyl amides (i.e., Belgian Patent No. 835,295).
- pharmaceutically acceptable salts of compounds of formula (I) are alkali metal salts such as the sodium or potassium salts, ammonium salts and organic amine salts such as those with procaine or dibenzylethylenediamine.
- the compounds of the invention can exist in the form of solvates for example hydrates, glycolates and alcoholates. It will be understood that such forms are within the scope of invention.
- Optical isomers are also possible such as with the mandeloyl or phenylglycyl substituents at position 7.
- the D-forms of these subgeneric groups are preferred.
- the compounds of the invention are most conveniently prepared by displacement of the acetoxy group of a known 7-acylamino-cephalosporanic acid of formula (II):- where R 1 is hydrogen or a group R as defined with reference to formula (I) in which any amino, carboxy, sulfo or hydroxy groups are optionally protected, with 1-(2-sulfamoylaminoethyl)-1,4-dihydro-5H-tetrazole-5-thione of formula (III):- and when R 1 is hydrogen, acylating the product with an acylating agent or active derivative of an acid ROH where R is as defined with reference to formula (I) thereafter removing any protecting groups and optionally thereafter converting the compound of formula (I) so obtained into an ester or a pharmaceutically acceptable salt or amide derivative.
- the acylation step can be carried out by known methods. N-acylation procedures may be found in Cephalosporins and Penicillins, Flynn, Academic Press, 1972; U.S. Patent Nos. 2,721,196 and 3,953,424; Belgian Patent No. 832,725; German Patent Nos. 2,127,285 and 2,406,165.
- Suitable protecting groups are known to the art (see “Protective Groups in Organic Chemistry", J.F.W. McOmie, Plenum Press, 1973, Chapters 2 and 3 for use of amino, carboxy, sulfo or hydroxyl protective groups).
- t-butyl (for COOH) or t-butoxy-carbonyl (for NH 2 ) groups are easily removed by treatment with trifluoroacetic acid.
- Certain compounds for formula (I) have shown antibacterial activity against both Gram positive and Gram negative bacteria with minimum inhibitory concentrations (MIC's) in vitro from 0.4 to 200 ⁇ g/ml.
- Test results for 7-D-(-)mandelamido-3-[1-(2-sulfamoylaminoethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid, sodium salt, dihydrate (A) and 7-[ ⁇ (Z)-(methoxyimino)-2-furanacetamido]-3-[1-(2-sulfamoylaminoethyl)tetrazolyl-5-ylthiomethyl]-3-cephem-4-carboxylic acid sodium salt (B) are:
- Compound A gave an ED 50 in mice of 0.26 against E. coli as well as 0.195 mg/kg against Kleb. pneumo. (s.c.).
- compositions having antibacterial activity which comprise a pharmaceutical carrier containing an active quanitity of a compound of formula (I) or a pharmaceutically acceptable salt or amide derivative thereof which is easily cleaved within the body, as well as their use in combating bacterial infections by administering such a composition to an infected animal, or human host in a non-toxic amount sufficient to combat such infections are also within this invention.
- the administration which, of course, should be of a non-toxic quantity of a compound of formula (1) may be oral or by parenteral injection for example subcutaneous, intramuscular or intravenous.
- the injection of suitably prepared sterile solutions or suspensions containing an effective non-toxic amount of the new cephalosporin compound is the preferred route of administration.
- the compounds of the invention used in this way are preferably formulated and administered in the same manner as other prior art cephalosporins such as cephazolin or cephalothin.
- the dosage regimen preferably comprises administration, preferably by injection, of an active but non-toxic quantity of a compound of formula (I) selected from the dosage unit range of from about 250 mg to 60C mg with the total daily dosage regimen being from about 750 mg to 6 g.
- the precise dosages are dependant upon the age and weight of the subject and on the susceptibility of the infection being treated in each individual. These can be determined by those skilled in the art based on the data disclosed herein compared with that available to the art attained with the known cephalosporins outlined herebefore.
- Example 2 illustrates the preparation of an intermediate for preparing the compounds. Temperatures are in degrees Centigrade (°C) unless otherwise stated.
- Triethylamine (1.0 g., 0.01 mol) was added to a suspension of 1.73 g. (0.005 mol) of the above tetrazole hydrochloride in 50 ml. of dry tetrahydrofuran. The suspension was cooled to 0°C. At that . temperature 0.885 g. (0.005 mol) of N-tert-butylsulfamoyl chloride in 40 ml. of dry tetrahydrofuran was added. After 30 minutes of stirring, the triethylamine hydrochloride was separated by filtration. The filtrate was evaporated to dryness.
- the tert-butyl compound (51.5 g.) was added to 500 mi. of trifluoroacetic acid and 250 ml. of m-dimethoxybenzene. The mixture was stirred at room temperature for 3 hours then stripped of the trifluoroacetic acid in vacuo. The dimethoxybenzene solution was diluted with 1.5 I. of ether to give a yellow precipitate. The solid was chromatographed on silica using 50:50 acetone/chloroform as eluant. The product-containing eluate was stripped. The residue was triturated with 100 ml.
- the sulfamoylamino intermediate (25.55 g., 0.065 mol) was suspended in 300 ml. of dry methanol and treated with 17 ml. of 25% sodium methoxide in methanol at room temperature with stirring. The methanol was stripped off in vacuo and the residue dissolved in 300 ml. of water. After filtering, the aqueous solution (pH 9.0) was extracted with ethyl acetate and then adjusted to pH 7.5 with dilute hydrochloric acid and again extracted with ethyl acetate.
- the aqueous layer was applied to an XAD-4 column (a nonionic resin which is a crosslinked copolymer of styrenedivinylbenzene) and eluted first with water and then 50% aqueous methanol.
- the methanol was stripped in vacuo from the pooled product-containing fractions.
- the remaining aqueous solution was treated with dilute hydrochloric acid to a pH of 1.5 and then extracted with ethyl acetate. After drying (MgS0 4 ) the extracts, the ethyl acetate was removed in vacuo to give a residue which was dissolved in dry methanol and adjusted to pH of 7.0 with 12.5% sodium methoxide in methanol.
- the product-containing effluent is evaporated to dryness to give a residue which is dissolved in a small amount of water and lyophilized to give 7-trifluoromethylthioacetamido-3-[1-(2-sulfamoylaminoethyl)tetrazole-5-ylthiomethyl]-3-cephem-4-carboxylic acid sodium salt.
- An injectable pharmaceutical composition is formed by adding sterile saline solution (2 ml.) to 500 mg. of the product of Example 1. This material is injected parenterally four times daily to a human patient infected with susceptible bacteria. Other compounds of this invention may be similarly used.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE8080200252T DE2861732D1 (en) | 1977-06-09 | 1978-06-09 | 1-(2-sulfamoylaminoethyl)-1,4-dihydro-5h-tetrazole-5-thione and its salts |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/805,197 US4117123A (en) | 1977-06-09 | 1977-06-09 | 7-Acylamino-3-[1-(2-sulfamidoethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acids |
US805197 | 1977-06-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP80200252A Division-Into EP0018669B1 (fr) | 1977-06-09 | 1978-06-09 | 1-(2-Sulfamylaminoéthyl)-1,4-dihydro-5H-tétrazole-5-thione et ses sels |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000100A1 EP0000100A1 (fr) | 1978-12-20 |
EP0000100B1 true EP0000100B1 (fr) | 1982-02-03 |
Family
ID=25190920
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP80200252A Expired EP0018669B1 (fr) | 1977-06-09 | 1978-06-09 | 1-(2-Sulfamylaminoéthyl)-1,4-dihydro-5H-tétrazole-5-thione et ses sels |
EP78300031A Expired EP0000100B1 (fr) | 1977-06-09 | 1978-06-09 | Acides 7-acylamino-3-(1-(2-sulfamylaminoéthyl)-tétrazole-5-ylthiométhyl)-3-céphem-4-carboxyliques, un procédé pour leur préparation et leurs compositions pharmaceutiques |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP80200252A Expired EP0018669B1 (fr) | 1977-06-09 | 1978-06-09 | 1-(2-Sulfamylaminoéthyl)-1,4-dihydro-5H-tétrazole-5-thione et ses sels |
Country Status (4)
Country | Link |
---|---|
US (1) | US4117123A (fr) |
EP (2) | EP0018669B1 (fr) |
JP (1) | JPS6053028B2 (fr) |
DE (1) | DE2861592D1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4171362A (en) * | 1975-10-30 | 1979-10-16 | Smithkline Corporation | 7-Acylamino-3-(sulfaminoalkyl substituted tetrazolylthiomethyl)cephalosporins antibacterial compositions containing them and methods of treating bacterial infections with them |
US4171368A (en) * | 1975-10-30 | 1979-10-16 | Smithkline Corporation | 7-Acylamino-3-(sulfaminoalkyl substituted tetrazolylthiomethyl)cephalosporins, antibacterial compositions containing them and methods of treating bacterial infections with them |
US4171433A (en) * | 1975-10-30 | 1979-10-16 | Smithkline Corporation | 7-Amino-3-(sulfaminoalkyl substituted tetrazolylthiomethyl)cephalosporin intermediates for preparing 7-acylamino cephalosporins |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR207752A1 (es) * | 1973-03-30 | 1976-10-29 | Fujisawa Pharmaceutical Co | Procedimiento para obtener acidos 7-amino-sustituido-3-tiometilsustituido-3-cefem-4-carboxilicos |
US4045438A (en) * | 1975-10-24 | 1977-08-30 | Yeda Research And Development Co. Ltd. | Cephalosporin antibiotics |
IL50546A (en) * | 1975-10-30 | 1980-07-31 | Smithkline Corp | 7-acyl-3-(1-(2-sulfaminoethyl)tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid derivatives and pharmaceutical compositions containing them |
US4025626A (en) * | 1975-12-09 | 1977-05-24 | Smithkline Corporation | 7-Acyl-3-(ureidoalkyl substituted tetrazolylthiomethyl)-cephalosporins |
US4101656A (en) * | 1976-07-12 | 1978-07-18 | Smithkline Corporation | 7β-Acylamino-3-(alkanesulfonamidoalkyl substituted tetrazolylthiomethyl) cephalosporins, antibacterial compositions containing them and methods of treating bacterial infections with them |
US4066762A (en) * | 1976-07-12 | 1978-01-03 | Smithkline Corporation | Derivatives of 7-(2-substituted-2-hydroxyiminoacetamido)-3-(1-substituted tetrazol-5-ylthiomethyl-3-cephem-4-carboxylic acid |
-
1977
- 1977-06-09 US US05/805,197 patent/US4117123A/en not_active Expired - Lifetime
-
1978
- 1978-06-05 JP JP53068753A patent/JPS6053028B2/ja not_active Expired
- 1978-06-09 DE DE7878300031T patent/DE2861592D1/de not_active Expired
- 1978-06-09 EP EP80200252A patent/EP0018669B1/fr not_active Expired
- 1978-06-09 EP EP78300031A patent/EP0000100B1/fr not_active Expired
Also Published As
Publication number | Publication date |
---|---|
JPS545994A (en) | 1979-01-17 |
US4117123A (en) | 1978-09-26 |
EP0000100A1 (fr) | 1978-12-20 |
DE2861592D1 (en) | 1982-03-11 |
EP0018669A1 (fr) | 1980-11-12 |
EP0018669B1 (fr) | 1982-04-14 |
JPS6053028B2 (ja) | 1985-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4066761A (en) | 7-Acyl-3-(ureidoalkyl substituted tetrazolylthiomethyl)cephalosporins | |
EP0000100B1 (fr) | Acides 7-acylamino-3-(1-(2-sulfamylaminoéthyl)-tétrazole-5-ylthiométhyl)-3-céphem-4-carboxyliques, un procédé pour leur préparation et leurs compositions pharmaceutiques | |
EP0000272B1 (fr) | Acides 7-acylamino-3-substitués-3-cephem-4-carboxyliques, procédé pour leur préparation, compositions pharmaceutiques les contenant | |
US4101656A (en) | 7β-Acylamino-3-(alkanesulfonamidoalkyl substituted tetrazolylthiomethyl) cephalosporins, antibacterial compositions containing them and methods of treating bacterial infections with them | |
US4174323A (en) | 1-(2-Sulfamidoethyl)-1,4-dihydro-5H-tetrazole-5-thione | |
US4117124A (en) | 7-Acylamino-3-[[3-(carboxymethyl)thio-1H-1,2,4-triazol-5-yl]thiomethyl]-3-cephem-4-carboxylic acids | |
US4140694A (en) | Intermediates for preparing 7-acyl-3-(sulfonic acid and sulfamoyl substituted tetrazolylthiomethyl)cephalosporins | |
US4057631A (en) | 7-(α-Substituted phenylacetamido)-3-(1-carboxymethylthioethyltetrazolyl-5-thiomethyl)-3-cephem-4-carboxylic acids | |
JPS6133825B2 (fr) | ||
US4079134A (en) | 7-Acylamino-3-(5-sulfomethyl-1,3,4-thiadiazol-2-ylthiomethyl)-3-cephem-4-carboxylic acids | |
US4064242A (en) | 7-Acylamino-3-[1-(2,3-dihydroxypropyl)tetrazole-5-ylthiomethyl]-3-cephem-4-carboxylic acids | |
US4174324A (en) | 3-(Carboxymethyl)thio-1H-1,2,4-triazol-5-thione | |
GB1604740A (en) | 7-isothiazolylthioacetamido-7-methoxycephalosporanic acid derivatives | |
US4210587A (en) | 7-Acylamino-3-[1-[2-(carboxymethylamino)ethyl]tetrazol-5-ylthio methyl]-3-cephem-4-carboxylic acids | |
US4083975A (en) | 7-Acylamino-3-(3-sulfomethyl-1,2,4-triazol-5-ylthiomethyl)-3-cephem-4-carboxylic acids | |
US4171362A (en) | 7-Acylamino-3-(sulfaminoalkyl substituted tetrazolylthiomethyl)cephalosporins antibacterial compositions containing them and methods of treating bacterial infections with them | |
US4118491A (en) | 7-Acyl-3-(sulfaminoalkyl substituted tetrazolylthiomethyl)cephalosporins, antibacterial compositions containing them and methods of treating bacterial infections with them | |
EP0048169A2 (fr) | Dérivés de céphalosporine bis-tétrazolylméthyl substitué, leur préparation et les compositions pharmaceutiques les contenant | |
GB1584861A (en) | Cephalosporin compounds | |
US4171368A (en) | 7-Acylamino-3-(sulfaminoalkyl substituted tetrazolylthiomethyl)cephalosporins, antibacterial compositions containing them and methods of treating bacterial infections with them | |
US4178288A (en) | Sulfaminoalkyl substituted tetrazole thiol intermediates for preparing cephalosporins | |
US4171433A (en) | 7-Amino-3-(sulfaminoalkyl substituted tetrazolylthiomethyl)cephalosporin intermediates for preparing 7-acylamino cephalosporins | |
US4218564A (en) | 7β-Hydroxy-3-heterocyclicthio-methyl cephalosporin intermediates | |
US4059591A (en) | Ureidoalkyl substituted tetrazole thiol intermediates for preparing cephalosporins | |
US4101657A (en) | Cephamycins as antibacterial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB LU NL SE Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB LU NL SE |
|
REF | Corresponds to: |
Ref document number: 2861592 Country of ref document: DE Date of ref document: 19820311 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19820630 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: SMITHKLINE BECKMAN CORPORATION |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Free format text: SMITHKLINE BECKMAN CORPORATION |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19830101 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19830408 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19840629 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19840630 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19840720 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19840731 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19840930 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19870610 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19870630 |
|
BERE | Be: lapsed |
Owner name: SMITHKLINE BECKMAN CORP. Effective date: 19870630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19880226 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19880301 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881117 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19890630 |
|
EUG | Se: european patent has lapsed |
Ref document number: 78300031.8 Effective date: 19880711 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |